CAS 2088323-16-2

4-amino-N-[4-[2-(dimethylamino)-2-oxoethyl]-2,3-dimethylphenyl]-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide

CAS : 2088323-16-2

Formule : C₂₆H₃₂N₈O₃

Degré de pureté : 98%

Masse moléculaire : 504.5841

Ref: IN-DA01LIAU

TAS0728

CAS : 2088323-16-2

TAS0728

Degré de pureté : ≥95%

Masse moléculaire : 504.58g/mol

Ref: 54-BUP09466

TAS0728

CAS : 2088323-16-2

TAS0728 is a HER2 inhibitor, with antitumor activity

Formule : C₂₆H₃₂N₈O₃

Degré de pureté : 97.78%

Couleur et forme : Solid

Masse moléculaire : 504.58

Ref: TM-T7819

TAS0728

CAS : 2088323-16-2

Formule : C₂₆H₃₂N₈O₃

Masse moléculaire : 504.60

Ref: 4Z-T-309001

TAS0728-d6

CAS : 2088323-16-2

Formule : C₂₆H₂₆D₆N₈O

Masse moléculaire : 510.63

Ref: 4Z-T-309002

TAS0728

CAS : 2088323-16-2

TAS0728 is an experimental drug that has potent antitumor activity and may be used for the treatment of cancer. TAS0728 does not have any known adverse effects on healthy cells, but it does have a potent effect on activated cardiac myocytes. TAS0728 has been shown to inhibit receptor-mediated signaling by blocking the epidermal growth factor (EGF) receptor, which may cause cancer resistance or growth factor. TAS0728 also blocks the epidermal growth factor (EGF), which can lead to cancer cell proliferation and increased tumor size. The powder diffraction spectrum of TAS0728 shows that it is composed of crystalline material with a molecular weight of 578.6 g/mol.

Formule : C₂₆H₃₂N₈O₃

Degré de pureté : Min. 95%

Masse moléculaire : 504.58 g/mol

Ref: 3D-NID32316